Advertisement

Annals of Surgical Oncology

, Volume 16, Issue 5, pp 1337–1343 | Cite as

Feasibility and Efficacy of Accelerated Weekly Concomitant Boost Postoperative Radiation Therapy Combined with Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer

  • Berrin Pehlivan
  • Francois Luthi
  • Oscar Matzinger
  • Michael Betz
  • Daniela Dragusanu
  • Shelley Bulling
  • Luc Bron
  • Philippe Pasche
  • Walter Seelentag
  • René O. Mirimanoff
  • Abderrahim Zouhair
  • Mahmut Ozsahin
Head and Neck Oncology

Background

The aim of this study was to assess feasibility and efficacy of weekly concomitant boost accelerated postoperative radiation therapy (PORT) with concomitant chemotherapy (CT) in patients with locally advanced head and neck cancer (LAHNC).

Methods and Materials

Conformal or intensity-modulated 66-Gy RT was performed in 5.5 weeks in 40 patients. Cisplatin was given at days 1, 22, and 43. Median follow-up was 36 months.

Results and Discussion

Grade 3 mucositis, dysphagia, and erythema was observed in ten (25%), nine (23%), and six (13%) patients, respectively. Grade 3 or more anemia was observed in two (6%) patients, and leukopenia in five (13%) patients. No grade 3 or 4 thrombocytopenia was observed. Grade 3 nephrotoxicity was observed in one patient (3%). No treatment-related mortality was observed. Grade 2 or more xerostomia and edema were observed in ten (25%) and one (3%) patient, respectively. Locoregional relapse occurred in eight patients, and seven patients developed distant metastases. Median time to locoregional relapse was 6 months. Three-year overall, disease-free survival, and locoregional control rates were 63%, 62%, and 81%, respectively. Multivariate analysis revealed that the only prognostic factor was nodal status.

Conclusion

Reducing overall treatment time using accelerated PORT/CT by weekly concomitant boost (six fractions per week) combined with concomitant cisplatin CT is easily feasible with acceptable morbidity.

Keywords

Overall Survival Radiation Therapy Oncology Group Concomitant Chemotherapy Locoregional Relapse Concomitant Boost 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–52.PubMedCrossRefGoogle Scholar
  2. 2.
    Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.PubMedCrossRefGoogle Scholar
  3. 3.
    Zelefsky MJ, Harrison LB, Fass DE, Armstrong JG, Shah JP, Strong EW. Postoperative radiation therapy for squamous cell carcinomas of the oral cavity and oropharynx: impact of therapy on patients with positive surgical margins. Int J Radiat Oncol Biol Phys. 1993;25:17–21.PubMedGoogle Scholar
  4. 4.
    Amdur RJ, Parsons JT, Mendenhall WM, Million RR, Cassisi NJ. Postoperative irradiation for squamous cell carcinoma of the head and neck: an analysis of treatment results and complications. Int J Radiat Oncol Biol Phys. 1989;16:25–36.PubMedGoogle Scholar
  5. 5.
    Tupchong L, Scott CB, Blitzer PH, Marcial VA, Lowry LD, Jacobs JR, et al. Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: Long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys. 1991;20:21–8.PubMedGoogle Scholar
  6. 6.
    Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postopeartive radiation plus chemotherapy trials of the EORTC 22931 and RTOG 9501. Head Neck. 2005;27:843–50.PubMedCrossRefGoogle Scholar
  7. 7.
    Bernier J. Current state-of-the-art for concurrent chemoradiation. Semin Radiat Oncol. 2009;19:3–10.PubMedCrossRefGoogle Scholar
  8. 8.
    Peters LJ, Withers HR. Applying radiobiological principles to combined modality treatment of head and neck cancer-the time factor. Int J Radiat Oncol Biol Phys. 1997;39:831–6.PubMedGoogle Scholar
  9. 9.
    Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7–16.PubMedCrossRefGoogle Scholar
  10. 10.
    Kajanti MJ, Holsti LR. Radical surgery and postoperative split-course radiotherapy in squamous cell carcinoma of the head and neck-factors influencing local control and survival. Acta Oncol. 1993;32:319–25.PubMedCrossRefGoogle Scholar
  11. 11.
    Zouhair A, Azria D, Pasche P, Stupp R, Chevalier J, Betz M, et al. Accelerated postoperative radiotherapy with weekly concomitant boost in patients with locally advanced head and neck cancer. Radiother Oncol. 2004;70:183–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Head and neck tumours. International Union Against Cancer (UICC), In: Sobin LH, Wittekind Ch,editors. TNM classification of malignant tumours, 6th ed. New York:Wiley-Liss; 2002. p.19–47.Google Scholar
  13. 13.
    Piquet MA, Ozsahin M, Larpin I, Zouhair A, Coti P, Monney M, et al. Early nutritional intervention in oropharyngeal cancer patients undergoing radiotherapy. Support Care Cancer. 2002;10:502–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRefGoogle Scholar
  15. 15.
    Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patients: part II. Br J Cancer. 1977;35:1–39.PubMedGoogle Scholar
  16. 16.
    Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187–220.Google Scholar
  17. 17.
    Bernier J. Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology? Nature Clin Practice Oncol. 2005;2:305–14.CrossRefGoogle Scholar
  18. 18.
    Horiot JC, Le Fur R, N’Guyen T, Chenal C, Schraub S, Alfonsi S, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: fnal analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 1992;25:231–40.PubMedCrossRefGoogle Scholar
  19. 19.
    Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843–54.PubMedCrossRefGoogle Scholar
  20. 20.
    Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, et al. Randomized trial addressing risk features and time factors of surgery and radiotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2001;51:571–78.PubMedGoogle Scholar
  21. 21.
    Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. Lancet. 2003;362:933–40.PubMedCrossRefGoogle Scholar
  22. 22.
    Sanguineti G, Richetti A, Bignardi M, Corvo' R, Gabriele P, Sormani MP, et al. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter phase III study. Int J Radiat Oncol Biol Phys. 2005;61:762–71.PubMedGoogle Scholar
  23. 23.
    Suwiński R, Bańkowska-Woźniak M, Majewski W, Idasiak A, Maciejewski A, Ziółkowska E, et al. Randomized clinical trial on continuous 7-days-a-week postoperative radiotherapy for high-risk squamous cell head-and-neck cancer: a report on acute normal tissue reactions. Radiother Oncol. 2006;80:27–32.PubMedCrossRefGoogle Scholar
  24. 24.
    Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798–804.PubMedCrossRefGoogle Scholar
  25. 25.
    Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000;18:1458–64.PubMedGoogle Scholar
  26. 26.
    Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:1161–71.PubMedGoogle Scholar
  27. 27.
    Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004;22:4665–73.PubMedCrossRefGoogle Scholar
  28. 28.
    Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95–06 Prospective Randomized Trial. J Clin Oncol. 2005;23:1125–35.PubMedCrossRefGoogle Scholar
  29. 29.
    Kutter J, Ozsahin M, Monnier P, Stupp R. Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma. Eur Arch Otorhinolayngol. 2005;262:1–7.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Berrin Pehlivan
    • 1
  • Francois Luthi
    • 2
  • Oscar Matzinger
    • 1
  • Michael Betz
    • 1
  • Daniela Dragusanu
    • 1
  • Shelley Bulling
    • 1
  • Luc Bron
    • 3
  • Philippe Pasche
    • 3
  • Walter Seelentag
    • 4
  • René O. Mirimanoff
    • 1
  • Abderrahim Zouhair
    • 1
  • Mahmut Ozsahin
    • 1
  1. 1.Department of Radiation OncologyUniversity Hospital Center, University of LausanneLausanneSwitzerland
  2. 2.Department of Medical OncologyUniversity Hospital Center, University of LausanneLausanneSwitzerland
  3. 3.Department of OtorhinolaryngologyUniversity Hospital Center, University of LausanneLausanneSwitzerland
  4. 4.Department of PathologyUniversity Hospital Center, University of LausanneLausanneSwitzerland

Personalised recommendations